Skip to content
Screener

Maze Therapeutics MAZE Q2 2026 earnings

Reported August 12, 2026 · After market close

EPS-$0.76Miss by $0.04
Revenue estimate$2.9M
EPS estimate-$0.72
“Looking ahead, we continue to prepare for the pivotal trial of MZE829. We are also advancing MZE782 toward a Phase 2 trial in CKD, which we expect to initiate in the first half of next year. With a strong balance sheet and expected cash runway into 2029, we are well positioned to execute against the clinical milestones in our pipeline.”
Jason Coloma

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$333.3K
EPS estimate-$0.79

Financials

Q2 2026

Income statement

See full
Operating income-$48.0M-31.7%
Net income-$44.7M-32.8%
EPS (diluted)-$0.76+1.3%

Balance sheet

See full
Cash & equivalents$202.6M-23.4%
Total debt$60.4M+142%
Total equity$453.1M+72.8%
Total assets$531.6M+75.2%

Cash flow

See full
Operating cash flow-$15.1M+49.9%
CapEx$107.0K-72.8%
Free cash flow-$15.2M+50.2%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.33B+28.9%
Enterprise value$1.19B+50.0%

Returns & leverage

See full
Return on equity-37.3%—
Debt / equity0.1×0.0×
Current ratio18.3×+4.7×

Segments

By geography

See full
US-—

FAQ

When did Maze Therapeutics report Q2 2026 earnings?
Maze Therapeutics (MAZE) reported Q2 2026 earnings on August 12, 2026 after market close.
What were Maze Therapeutics's Q2 2026 revenue and EPS?
Maze Therapeutics reported eps of $-0.76 for Q2 2026.
Did Maze Therapeutics beat estimates in Q2 2026?
EPS missed the consensus estimate of $-0.72 by $0.04.
How did Maze Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 1.3% from $-0.77.
Where can I find Maze Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-344878) and the 10-Q periodic report (0001193125-26-344903) directly on SEC EDGAR. The filing index links above go to sec.gov.